The Drp1 inhibitor DRP1i2 confers cardioprotection against doxorubicin-induced cardiotoxicity
Anthracyclines such as doxorubicin are highly effective chemotherapeutic agents, but their clinical use is limited by dose-dependent cardiotoxicity associated with mitochondrial dysfunction. Dysregulated mitochondrial dynamics, particularly excessive dynamin-related protein 1 (Drp1)-mediated fission, has been implica...